- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cardiff Oncology Inc (CRDF)
Cardiff Oncology Inc stock price live, this page displays NASDAQ CRDF stock exchange data. View the CRDF premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cardiff Oncology Inc real time stock price chart below.
What Is the Cardiff Oncology Inc Stock Price Today?
The Cardiff Oncology Inc stock price today is 0.963.
What Is the Stock Symbol for Cardiff Oncology Inc?
The stock symbol for Cardiff Oncology Inc is "CRDF."
What Stock Exchange Does Cardiff Oncology Inc Trade On?
Cardiff Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Cardiff Oncology Inc a Good Stock to Buy?
Determining whether Cardiff Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRDF quote. (ISIN: US14147L1089)
What Is the Cardiff Oncology Inc Stock Price Today?
The Cardiff Oncology Inc stock price today is 0.963.
What Is the Stock Symbol for Cardiff Oncology Inc?
The stock symbol for Cardiff Oncology Inc is "CRDF."
What Stock Exchange Does Cardiff Oncology Inc Trade On?
Cardiff Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Cardiff Oncology Inc a Good Stock to Buy?
Determining whether Cardiff Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CRDF quote. (ISIN: US14147L1089)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.960
1.020
52 wk Range
0.757
3.310
CRDF is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9601.020
52 wk Range
0.7573.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CRDF Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
5.750
Upside
+497.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
TrovaGene Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- TrovaGene Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
- Form 4 Cardiff Oncology Inc For: 16 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
5 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.750
(+497.09% Upside)
Cardiff Oncology Inc Earnings Call Summary for Q4/2024
- Cardiff Oncology raised $40M, extending cash runway to Q1 2027 with $91.7M in reserves as of Dec 31, 2024
- ONVANSERTIB showed promising results in metastatic colorectal cancer trials, positioning Cardiff as a potential market leader
- Stock declined 8.97% in regular trading but rebounded 2.71% after hours, reflecting mixed market sentiment
- Company plans to release additional clinical data in H1 2025 and engage with FDA on registrational strategy for ONVANSERTIB
- CEO expressed optimism about ONVANSERTIB's potential to change treatment paradigm for RAS mutated MCRC patients
Last Updated: 2025-02-27, 05:24 p/m
Read Full TranscriptEarnings
Latest Release
Aug 11, 2026
EPS / Forecast
-0.14 / -0.12
Revenue / Forecast
100K / 62.78K
Compare CRDF to Peers and Sector
Metrics to compare | CRDF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRDFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.6x | −10.9x | −0.4x | |
PEG Ratio | −0.05 | −0.03 | 0.00 | |
Price/Book | 2.5x | 4.3x | 2.6x | |
Price / LTM Sales | 129.6x | 17.2x | 3.1x | |
Upside (Analyst Target) | - | 32.1% | 47.8% | |
Fair Value Upside | Unlock | −9.7% | 6.2% | Unlock |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Cardiff Oncology (CRDF) Stock Price Today?
The Cardiff Oncology stock price today is 0.963 USD.
What Stock Exchange Does Cardiff Oncology Trade On?
Cardiff Oncology is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cardiff Oncology?
The stock symbol for Cardiff Oncology is "CRDF."
What Is the Cardiff Oncology Market Cap?
As of today, Cardiff Oncology market cap is 67.280M USD.
What Is Cardiff Oncology's Earnings Per Share (TTM)?
The Cardiff Oncology EPS (TTM) is -0.596.
When Is the Next Cardiff Oncology Earnings Date?
Cardiff Oncology will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is CRDF a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Cardiff Oncology Stock Split?
Cardiff Oncology has split 3 times.
How Many Employees Does Cardiff Oncology Have?
Cardiff Oncology has 31 employees.
What is the current trading status of Cardiff Oncology (CRDF)?
As of Aug 15, 2026, Cardiff Oncology (CRDF) is trading at a price of 0.963 USD, with a previous close of 0.984 USD. The stock has fluctuated within a day range of 0.960 USD to 1.020 USD, while its 52-week range spans from 0.757 USD to 3.310 USD.
What Is Cardiff Oncology (CRDF) Price Target According to Analysts?
The average 12-month price target for Cardiff Oncology is 5.750 USD, with a high estimate of 12 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +497.09% Upside potential.
What Is the CRDF Premarket Price?
CRDF's last pre-market stock price is 0.976 USD. The pre-market share volume is 4,150.000, and the stock has decreased by -0.008, or -0.810%.
What Is the CRDF After Hours Price?
CRDF's last after hours stock price is 1.000 USD, the stock has decreased by 0.037, or 3.840%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.